Abstract | PURPOSE: METHODS AND MATERIALS: Groups of 8 or 9 athymic male nude mice (6-8 weeks old) were implanted with s.c. U87 xenograft tumors (4 x 10(6) cells) and then randomized to 10 treatment groups receiving increasing doses of p.o. IPdR (0, 100, 250, 500, and 1000 mg/kg/d) administered once daily (q.d.) x 14 days with or without radiotherapy (RT) (0 or 2 Gy/d x 4 days) on days 11-14 of IPdR treatment. Systemic toxicity was determined by body weight measurements during and after IPdR treatment. Tumor response was assessed by changes in tumor volumes. RESULTS:
IPdR alone at doses of > or =500 mg/kg/d resulted in moderate inhibition of tumor growth. The combination of IPdR plus RT resulted in a significant IPdR dose-dependent tumor growth delay, with the maximum radiosensitization using > or =500 mg/kg/d. IPdR doses of 500 and 1000 mg/kg/d resulted in transient 5-15% body weight loss during treatment. CONCLUSIONS: In U87 human glioblastoma s.c. xenografts, p.o. IPdR given q.d. x 14 days and RT given 2 Gy/d x 4 days (days 11-14 of IPdR treatment) results in a significant tumor growth delay in an IPdR dose-dependent pattern. The use of p.o. IPdR plus RT holds promise for Phase I/II testing in patients with high-grade gliomas.
|
Authors | Timothy J Kinsella, Michael T Kinsella, Yuji Seo, Gregory Berk |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 69
Issue 4
Pg. 1254-61
(Nov 15 2007)
ISSN: 0360-3016 [Print] United States |
PMID | 17967315
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Prodrugs
- Pyrimidine Nucleosides
- Radiation-Sensitizing Agents
- ropidoxuridine
|
Topics |
- Animals
- Body Weight
(drug effects)
- Brain Neoplasms
(drug therapy, pathology, radiotherapy)
- Cell Line, Tumor
- Dose-Response Relationship, Drug
- Glioblastoma
(drug therapy, pathology, radiotherapy)
- Humans
- Male
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Prodrugs
(therapeutic use)
- Pyrimidine Nucleosides
(therapeutic use)
- Radiation-Sensitizing Agents
(therapeutic use)
- Random Allocation
- Tumor Burden
(drug effects, radiation effects)
- Xenograft Model Antitumor Assays
(methods)
|